Everything below concerns actin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-01. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
==== MVA ==== Modified vaccinia Ankara (MVA, German: Modifiziertes Vakziniavirus Ankara) is a replication-incompetent variant of vaccinia that was developed in West Germany through serial passage. The original Ankara strain of vaccinia was maintained at the vaccine institute in Ankara, Turkey on donkeys and cows. The Ankara strain was taken to West Germany in 1953, where Herrlich and Mayr grew it on chorioallantoic membrane at LMU Munich. After 572 serial passages, the vaccinia virus had lost over 14% of its genome and could no longer replicate in human cells. MVA was used in West Germany in 1977–1980, but the eradication of smallpox ended the vaccination campaign after only 120,000 doses. MVA stimulates the production of fewer antibodies than replicating vaccines. During the smallpox eradication campaign, MVA was considered to be a pre-vaccine that would be administered before a replicating vaccine to reduce the side effects, or an alternative vaccine that could be safely given to people at high risk from a replicating vaccine. Japan evaluated MVA and rejected it due to its low immunogenicity, deciding to develop its own attenuated vaccine instead. In the 2000s, MVA was tested in animal models at much higher dosages. When MVA is given to monkeys at 40 times the dosage of Dryvax, it stimulates a more rapid immune response while still causing lesser side effects.
== Role in epileptic seizures == AMPA receptors play a key role in the generation and spread of epileptic seizures. Activation of AMPARs by agonists such as kainic acid, a convulsant that is widely used in epilepsy research, has been shown to induce seizures in both animal models and humans, emphasizing their contribution to epileptogenesis. Conversely, antagonists targeting AMPARs have demonstrated efficacy in suppressing seizure activity, highlighting their potential as therapeutic agents in epilepsy management.
=== Simmering hostilities === Although the Vaal uprising marked the beginning of an open and sustained revolt, it was preceded by an "underground war" or "series of localised confrontations", for example clashes in Pietermaritzburg in 1982; in Durban and Mdantsane in 1983; and in Crossroads, Atteridgeville, Cradock, Tumahole, and the East Rand earlier in 1984. Over the same period, in Soweto and some other areas, there was a demonstrable upswing in a longstanding habit of persecution of black local councillors. The boycott of the 1984 election, held in the last week of August, was accompanied by large-scale protests, resulting in a large number of arrests. Some of the candidates for the Tricameral Parliament were also targeted in petrol bomb attacks.
Sources: en.wikipedia.org
=== 18 April === Two people were killed in separate Russian attacks in Donetsk Oblast. Russia claimed to have shot down five Ukrainian balloons carrying explosives over Belgorod and Voronezh Oblasts. A Polish national was arrested in Poland on suspicion of spying for Russia as part of a plot to assassinate Zelenskyy during his visit there, following a tip from Ukrainian authorities. EU foreign policy chief Josep Borrell called on EU member states to send anti-missile systems to Ukraine.
== Centers and Institutes for Advanced Research & Education == Center for Advanced Photonics Research Center for Biophysics and Computational Biology Center for Computational Genetics and Genomics Center for Data Analytics and Biomedical Informatics Center for Materials Theory Institute for Computational Molecular Science Sbarro Health Research Organization
Advasil Conform: Polyurethane film backing and self-adhesive Bapscarcare T: Self-adhesive Cica-care: Soft, self-adhesive, and semi-occlusive with backing Ciltech: Polyurethane film backing and self-adhesive Dermatix: Self-adhesive (transparent or fabric-backed) Mepiform: Polyurethane film backing and self-adhesive Myscar: Medical grade silicone Scar FX: Self-adhesive and transparent Silgel: Thin and transparent Scarcura: Self-adhesive, soft
=== Social anxiety disorder === SSRIs show some evidence of effectiveness for social anxiety disorder, including reducing relapse and disability, but the overall quality of evidence is low to moderate and tolerability is slightly lower than placebo.
Sources: en.wikipedia.org
In addition, a very thorny issue was that of "replacements", a compensation that Peru would make to Colombian troops for the casualties suffered by them during the war, by exchanging Peruvian citizens and expatriating them to Gran Colombia, exorbitant and inhuman requirement, given that the war had already ended. Given this, Bolívar demobilized most of the Peruvian units (about five thousand who replaced the Gran Colombian casualties) and after the capitulation of Callao, presented on February 10, 1826, the demand to send 6,000 Peruvian recruits to serve Venezuela, sending the first contingents in July, probably no more than 3,000, officially to reinforce the defenses against a possible French invasion (Cien Mil Hijos de San Luis) but in reality it was to confront General Páez, who had started La Cosiata (a separatist movement in Venezuela) and also to demilitarize Peru so that it is not a future threat to its continental projects in the Patria Grande. The troops sent there, due to the distance and lack of knowledge of the language (the majority were indigenous who barely knew Spanish) made desertion or mutiny difficult, many of those sent dying due to the weather and tropical diseases. It is known that some survivors were repatriated of New Granada and Venezuela in 1852 and 1857 respectively. Due to the lifelong and authoritarian constitutions promulgated for Peru and Bolivia, the Liberator would be accused of using his armies to impose political systems, in a republican imperialism, rather than making countries independent.
An exudate is a fluid released by an organism through pores or a wound, a process known as exuding or exudation. Exudate is derived from exude 'to ooze' from Latin exsūdāre 'to (ooze out) sweat' (ex- 'out' and sūdāre 'to sweat').
In 1984, the chain returned to the U.S. with a location in Tonawanda, New York. Starting in the mid-1990s, however, the chain began expanding in the U.S. by acquiring former locations from fast-food chains. In 1996 and 1997, thirty-seven former Rax locations in Ohio, Kentucky, and West Virginia were bought by Wendy's International Inc.; 30 of these were converted to Tim Hortons, while the others became Wendy's franchise locations. Thirty-five closed Hardee's stores in the Detroit area were also purchased with the intention of being converted. By 2004, the chain had also acquired 42 Bess Eaton coffee and donut restaurants in southern New England. Several combination Wendy's/Tim Hortons units were opened in the US; both in the "traditional" markets of Maine and Buffalo, where there were well over 180 locations as of 2011, and in the markets entered through acquisition. In October 2008, Tim Hortons announced a plan to add 82 locations in Tops Markets stores in the United States. On July 13, 2009, Tim Hortons opened stores in New York City at former Dunkin' Donuts locations operated by the Riese Organization. One of the stores is at Madison Square Garden, where Horton played as a member of the New York Rangers from 1969 to 1971. In November 2010, Tim Hortons announced it was closing 36 stores in the northeastern United States due to high competition with New England–based Dunkin' Donuts and Au Bon Pain.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.